Skip to main content

Prostate Fossa Radiotherapy (NCT07313241)

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER): a one-minute explainerNCT073132411 min

Prostate Fossa Radiotherapy trial for Prostate Cancer (NCT07313241). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adult men with persistent or rising PSA after prostate removal, without confirmed regional or distant spread. Previous pelvic radiation is excluded.

The idea: everyone receives five prostate-bed radiation sessions. PSA is checked five weeks after treatment starts. Responders enter observation; nonresponders receive five pelvic-node radiation sessions and four months of androgen-deprivation therapy. This tests whether extra treatment can be reserved for nonresponders. Researchers compare progression outcomes with historical data.

This phase 2 study plans 68 patients. Aurelie Garant leads at UT Southwestern, Dallas, the sole recruiting US site.

Public record; not medical advice.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.